News | April 03, 2022
WHO suspends supply of Covaxin under Covax facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
The plant is scheduled to come on stream in September 2024
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Subscribe To Our Newsletter & Stay Updated
